1st Counsel – Lifestyle
Author:
NovelMed Therapeutics Inc
NovelMed Therapeutics Announces Regulatory Clearance for Subcutaneous Ruxoprubart and Reports Positive Phase II Intravenous Monotherapy Results in PNH
March 9, 2026